WO2004062653A3 - The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis - Google Patents

The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis Download PDF

Info

Publication number
WO2004062653A3
WO2004062653A3 PCT/US2004/000037 US2004000037W WO2004062653A3 WO 2004062653 A3 WO2004062653 A3 WO 2004062653A3 US 2004000037 W US2004000037 W US 2004000037W WO 2004062653 A3 WO2004062653 A3 WO 2004062653A3
Authority
WO
WIPO (PCT)
Prior art keywords
estrogen receptor
treatment
sclerosis
multiphe
receptor alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/000037
Other languages
French (fr)
Other versions
WO2004062653A2 (en
Inventor
M Merle Elloso
Robert Mitchell
Douglas C Harnish
Steven J Adelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to BR0406643-0A priority Critical patent/BRPI0406643A/en
Priority to MXPA05007317A priority patent/MXPA05007317A/en
Priority to AU2004204675A priority patent/AU2004204675A1/en
Priority to EP04700191A priority patent/EP1585507A2/en
Priority to JP2006500772A priority patent/JP2006515616A/en
Priority to CA002512021A priority patent/CA2512021A1/en
Publication of WO2004062653A2 publication Critical patent/WO2004062653A2/en
Publication of WO2004062653A3 publication Critical patent/WO2004062653A3/en
Priority to NO20053156A priority patent/NO20053156L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods of treating an autoimmune pathology in a mammal, comprising administering an agent with estrogen receptor a agonist activity in particular a selective estrogen receptor modulator, to the mammal in an amount sufficient to decrease production of TH-1 and/or TH-2 cytokines. Also provided is a method of selecting compounds useful for the treatment of multiple sclerosis, comprising selecting a compound which has estrogen receptor a agonist activity.
PCT/US2004/000037 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis Ceased WO2004062653A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0406643-0A BRPI0406643A (en) 2003-01-06 2004-01-05 Use of alpha estrogen receptor modulators for the treatment of multiple sclerosis
MXPA05007317A MXPA05007317A (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis.
AU2004204675A AU2004204675A1 (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
EP04700191A EP1585507A2 (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
JP2006500772A JP2006515616A (en) 2003-01-06 2004-01-05 Use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
CA002512021A CA2512021A1 (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis
NO20053156A NO20053156L (en) 2003-01-06 2005-06-28 Use of estrogen receptor alpha modulators for the treatment of multiple sclerosis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43812303P 2003-01-06 2003-01-06
US60/438,123 2003-01-06

Publications (2)

Publication Number Publication Date
WO2004062653A2 WO2004062653A2 (en) 2004-07-29
WO2004062653A3 true WO2004062653A3 (en) 2004-11-04

Family

ID=32713279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000037 Ceased WO2004062653A2 (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis

Country Status (14)

Country Link
US (1) US20040167112A1 (en)
EP (1) EP1585507A2 (en)
JP (1) JP2006515616A (en)
KR (1) KR20050091058A (en)
CN (1) CN1723013A (en)
AU (1) AU2004204675A1 (en)
BR (1) BRPI0406643A (en)
CA (1) CA2512021A1 (en)
EC (1) ECSP055950A (en)
MX (1) MXPA05007317A (en)
NO (1) NO20053156L (en)
RU (1) RU2005125043A (en)
WO (1) WO2004062653A2 (en)
ZA (1) ZA200505400B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082322A1 (en) * 2004-10-09 2009-03-26 The Regents Of The University Of Michigan Gender Differences in Experimental Aortic Aneurysm Formation
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
WO2016021601A1 (en) * 2014-08-04 2016-02-11 日東電工株式会社 Immune-induction-promoting composition including nuclear receptor ligand, and vaccine pharmaceutical composition
AU2017308131A1 (en) * 2016-08-12 2019-03-07 The Regents Of The University Of California Remyelination therapies
KR102817163B1 (en) * 2022-08-04 2025-06-05 고려대학교 산학협력단 Composition for preventing or treating inflammatory skin disease comprising bazedoxifen as an active ingredient

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
EP0664123A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of autoimmune diseases
EP0664125A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of myeloperoxidase activity
EP0668075A2 (en) * 1993-12-21 1995-08-23 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
WO1996005823A1 (en) * 1994-08-22 1996-02-29 Eli Lilly And Company Methods of inhibiting demyelinating and dysmyelinating diseases
EP0724879A2 (en) * 1995-02-06 1996-08-07 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiopenes for inhibiting effects of IL-6
EP0747052A2 (en) * 1995-06-07 1996-12-11 Eli Lilly And Company Methods of modulating NF-KB transcription factor
EP0966965A1 (en) * 1998-06-17 1999-12-29 Eli Lilly And Company Methods for reducing levels of homocysteine and C-reactive protein
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
WO2002085374A1 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
EP0664123A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of autoimmune diseases
EP0664125A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of myeloperoxidase activity
EP0668075A2 (en) * 1993-12-21 1995-08-23 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
WO1996005823A1 (en) * 1994-08-22 1996-02-29 Eli Lilly And Company Methods of inhibiting demyelinating and dysmyelinating diseases
EP0724879A2 (en) * 1995-02-06 1996-08-07 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiopenes for inhibiting effects of IL-6
EP0747052A2 (en) * 1995-06-07 1996-12-11 Eli Lilly And Company Methods of modulating NF-KB transcription factor
EP0966965A1 (en) * 1998-06-17 1999-12-29 Eli Lilly And Company Methods for reducing levels of homocysteine and C-reactive protein
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
WO2002085374A1 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
APELGREN L D ET AL: "The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice", CELLULAR IMMUNOLOGY 1996 UNITED STATES, vol. 173, no. 1, 1996, pages 55 - 63, XP001190866, ISSN: 0008-8749 *

Also Published As

Publication number Publication date
JP2006515616A (en) 2006-06-01
ZA200505400B (en) 2006-12-27
WO2004062653A2 (en) 2004-07-29
CN1723013A (en) 2006-01-18
ECSP055950A (en) 2006-01-16
US20040167112A1 (en) 2004-08-26
NO20053156D0 (en) 2005-06-28
AU2004204675A1 (en) 2004-07-29
CA2512021A1 (en) 2004-07-29
KR20050091058A (en) 2005-09-14
NO20053156L (en) 2005-09-08
EP1585507A2 (en) 2005-10-19
MXPA05007317A (en) 2005-09-30
RU2005125043A (en) 2006-01-27
BRPI0406643A (en) 2005-12-06

Similar Documents

Publication Publication Date Title
MY149856A (en) Therapeutic agent for mesothelioma
AU2003256449A8 (en) System and method for managing bandwidth utilization
AU2003225279A1 (en) System and method for enterprise application interactions
SG138449A1 (en) Enumeration method for the link clock rate and the pixel/audio clock rate
AU2003274601A1 (en) Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
GB0214265D0 (en) System and method for auditing system call events with system call wrappers
AU2003242146A1 (en) Method of storing hydrogen, hydrogen inclusion compound and process for producing the same
MX2007001035A (en) Method of producing a composition, composition and its use.
AU2003296082A1 (en) Liquid mixture, structure, and method for forming structure
AU2003262033A8 (en) Method for managing use of storage region by application
WO2004103288A3 (en) Method of preventing recurrent miscarriages
AU2003250753A1 (en) Method for producing organic compounds containing poly-dopo, and the use of the same
AU2003208231A1 (en) Method and system for correlating telephone calls with information delivery
WO2004062653A3 (en) The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
GB0405595D0 (en) Method and system for affinity management
AU2003250555A1 (en) Apparatus and method for providing telephone number management service and avatar
IL182166A0 (en) Business process management system and method
TW200716159A (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
AP2144A (en) Method and arrangement for implementing minimum activity during discontinuous transmission.
GB0525250D0 (en) Telephone system,switching system and management method of telephone system
AU2003241375A8 (en) Method for identifying modulators of sulfotransferase activity
AU2003249314A1 (en) Catalyst regeneration by treatment with an oxidizing agent
PL1663997T3 (en) 1h-azolyl-methyl-amides, method for the production thereof and use thereof as nitrification inhibitors
EP1786816A4 (en) Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
GB2412549C (en) Call device, call control system, call management system, and call control method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501268

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 540828

Country of ref document: NZ

Ref document number: 169308

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2774/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004204675

Country of ref document: AU

Ref document number: 2512021

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/05400

Country of ref document: ZA

Ref document number: 1020057012561

Country of ref document: KR

Ref document number: 200505400

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20048018762

Country of ref document: CN

Ref document number: PA/a/2005/007317

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006500772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 05070253

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2004204675

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200501096

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2004700191

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005125043

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057012561

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004700191

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0406643

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004700191

Country of ref document: EP